Interim data from a phase II study produced positive safety and efficacy data for bel-sar (belzupacap sarotalocan) for the first-line treatment of patients with early-stage choroidal melanoma. With an average of nine months of follow up, the interim data shows the evaluation of two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal route of administration.
Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
